Stavros Garantziotis

Prof. Stavros Garantziotis

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2015 in International Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
JCJaime M. Cyphert
Jaime M. Cyphert
CTCarol S. Trempus
Carol S. Trempus
SGStavros Garantziotis
Stavros Garantziotis
Hyaluronan signaling properties are unique among other biologically active molecules, that they are apparently not influenced by postsynthetic molecular modification, but by hyaluronan fragment size. This review summarizes the current knowledge about the generation of hyaluronan fragments of different size and size-dependent differences in hyaluronan signaling as well as their downstream biological effects.

1 October 2015 in Environment International
Verified
Journal Article
Closed access
KTKristina A. Thayer
Kristina A. Thayer
DDDaniel R. Doerge
Daniel R. Doerge
DHDawn Hunt
Dawn Hunt
SSShepherd H. Schurman
Shepherd H. Schurman
NTNathan C. Twaddle
Nathan C. Twaddle
LBLinda S. Birnbaum
Linda S. Birnbaum

1 February 2015 in Environmental Health Perspectives
Verified
Journal Article
Open access
KHKate Hoffman
Kate Hoffman
SGStavros Garantziotis
Stavros Garantziotis
LBLinda S. Birnbaum
Linda S. Birnbaum
HSHeather M. Stapleton
Heather M. Stapleton
Background: Organophosphate flame retardants (PFRs) are becoming popular replacements for the phased-out polybrominated diphenyl ether (PBDE) mixtures, and they are now commonly detected in indoor environments. However, little is known about human exposure to PFRs because they cannot be easily measured in blood or serum. Objectives: To investigate relationships between the home environment and internal exposure, we assessed associations between two PFRs, tris(1,3-dichloropropyl) phosphate (TDCIPP) and triphenyl phosphate (TPHP), in paired hand wipe and dust samples and concentrations of their metabolites in urine samples (n = 53). We also assessed short-term variation in urinary metabolite concentrations (n = 11 participants; n = 49 samples). Methods: Adult volunteers in North Carolina, USA, completed questionnaires and provided urine, hand wipe, and household dust samples. PFRs and PBDEs were measured in hand wipes and dust, and bis(1,3-dichloropropyl) phosphate (BDCIPP) and diphenyl phosphate (DPHP), metabolites of TDCIPP and TPHP, were measured in urine. Results: TDCIPP and TPHP were detected frequently in hand wipes and dust (> 86.8%), with geometric mean concentrations exceeding those of PBDEs. Unlike PBDEs, dust TDCIPP and TPHP levels were not associated with hand wipes. However, hand wipe levels were associated with urinary metabolites. Participants with the highest hand wipe TPHP mass, for instance, had DPHP levels 2.42 times those of participants with the lowest levels (95% CI: 1.23, 4.77). Women had higher levels of DPHP, but not BDCIPP. BDCIPP and DPHP concentrations were moderately to strongly reliable over 5 consecutive days (intraclass correlation coefficients of 0.81 and 0.51, respectively). Conclusions: PFR exposures are widespread, and hand-to-mouth contact or dermal absorption may be important pathways of exposure. Citation: Hoffman K, Garantziotis S, Birnbaum LS, Stapleton HM. 2015. Monitoring indoor exposure to organophosphate flame retardants: hand wipes and house dust. Environ Health Perspect 123:160–165; http://dx.doi.org/10.1289/ehp.1408669

18 September 2008 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JHJohn W. Hollingsworth
John W. Hollingsworth
SMShuichiro Maruoka
Shuichiro Maruoka
KBKathy Boon
Kathy Boon
SGStavros Garantziotis
Stavros Garantziotis
ZLZhuowei Li
Zhuowei Li
DSDavid A. Schwartz
David A. Schwartz
Asthma is a complex heritable disease that is increasing in prevalence and severity, particularly in developed countries such as the United States, where 11% of the population is affected. The contribution of environmental and genetic factors to this growing epidemic is currently not well understood. We developed the hypothesis, based on previous literature, that changes in DNA methylation resulting in aberrant gene transcription may enhance the risk of developing allergic airway disease. Our findings indicate that in mice, a maternal diet supplemented with methyl donors enhanced the severity of allergic airway disease that was inherited transgenerationally. Using a genomic approach, we discovered 82 gene-associated loci that were differentially methylated after in utero supplementation with a methyl-rich diet. These methylation changes were associated with decreased transcriptional activity and increased disease severity. Runt-related transcription factor 3 (Runx3), a gene known to negatively regulate allergic airway disease, was found to be excessively methylated, and Runx3 mRNA and protein levels were suppressed in progeny exposed in utero to a high-methylation diet. Moreover, treatment with a demethylating agent increased Runx3 gene transcription, further supporting our claim that a methyl-rich diet can affect methylation status and consequent transcriptional regulation. Our findings indicate that dietary factors can modify the heritable risk of allergic airway disease through epigenetic mechanisms during a vulnerable period of fetal development in mice.

21 June 2012 in ACS Nano
Verified
Journal Article
Closed access
SHSalik Hussain
Salik Hussain
FAFaris Al-Nsour
Faris Al-Nsour
ARAnnette B. Rice
Annette B. Rice
JMJamie Marshburn
Jamie Marshburn
BYBrenda Yingling
Brenda Yingling
SGStavros Garantziotis
Stavros Garantziotis

31 January 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RCRaymond J. Chan
Raymond J. Chan
JWJoan Webster
Joan Webster
BCBryan Chung
Bryan Chung
LMLouise Marquart
Louise Marquart
MAMuhtashimuddin Ahmed
Muhtashimuddin Ahmed
SGStavros Garantziotis
Stavros Garantziotis
Radiation-induced skin reaction (RISR) is a common side effect that affects the majority of cancer patients receiving radiation treatment. RISR is often characterised by swelling, redness, pigmentation, fibrosis, and ulceration, pain, warmth, burning, and itching of the skin. The aim of this systematic review was to assess the effects of interventions which aim to prevent or manage RISR in people with cancer. We searched the following databases up to November 2012: Cochrane Skin Group Specialised Register, CENTRAL (2012, Issue 11), MEDLINE (from 1946), EMBASE (from 1974), PsycINFO (from 1806), CINAHL (from 1981) and LILACS (from 1982). Randomized controlled trials evaluating interventions for preventing or managing RISR in cancer patients were included. The primary outcomes were development of RISR, and levels of RISR and symptom severity. Secondary outcomes were time taken to develop erythema or dry desquamation; quality of life; time taken to heal, a number of skin reaction and symptom severity measures; cost, participant satisfaction; ease of use and adverse effects. Where appropriate, we pooled results of randomized controlled trials using mean differences (MD) or odd ratios (OR) with 95% confidence intervals (CI). Forty-seven studies were included in this review. These evaluated six types of interventions (oral systemic medications; skin care practices; steroidal topical therapies; non-steroidal topical therapies; dressings and other). Findings from two meta-analyses demonstrated significant benefits of oral Wobe-Mugos E for preventing RISR (OR 0.13 (95% CI 0.05 to 0.38)) and limiting the maximal level of RISR (MD -0.92 (95% CI -1.36 to -0.48)). Another meta-analysis reported that wearing deodorant does not influence the development of RISR (OR 0.80 (95% CI 0.47 to 1.37)). Despite the high number of trials in this area, there is limited good, comparative research that provides definitive results suggesting the effectiveness of any single intervention for reducing RISR. More research is required to demonstrate the usefulness of a wide range of products that are being used for reducing RISR. Future efforts for reducing RISR severity should focus on promising interventions, such as Wobe-Mugos E and oral zinc.